ADIL Adial Pharmaceuticals Inc. Quarterly EPS earnings growth

Adial Pharmaceuticals is developing an alcoholism treatment system via the drug AD04, utilizing automated clinical data analysis to optimize therapy. On GURU.Markets, the quarterly earnings per share growth metric visualizes the results of these processes, where the -143.50 mark serves as the key value. This approach is complemented by an ESG strategy that integrates the environmental safety of laboratories with the social mission of protecting public health.

adialpharma.com (ADIL) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 10/29/2026

ADIL (Adial Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:

Price Chart Adial|ADIL - Consensus Target

- market capitalization data:

Market Capitalization Adial Pharmaceuticals, Inc.|ADIL - Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share Adial Pharmaceuticals|ADIL - Accounting Capitalization|Market Capitalization to Book Value Ratio adialpharma.com|ADIL - Company Total Asset Base

- debt and liquidity data:

- earnings and valuation multiples indicators:

ADIL - Final Profit|Projected Future Earnings Adial Pharmaceuticals|ADIL - P/E Multiple|Future Price to Earnings Adial|ADIL - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adial Pharmaceuticals, Inc.|ADIL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Adial Pharmaceuticals|ADIL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth adialpharma.com|ADIL - Net earnings per share growth this year|Earnings growth forecast for next year Adial Pharmaceuticals

- company sales and revenue statistics:

ADIL - Company Total Revenue|Company Future Sales Volume Adial Pharmaceuticals, Inc.|ADIL - P/S Multiple|Forward Price-to-Revenue Multiple Adial

Fundamental valuation:adialpharma.com, ADIL

The uniqueness of its genetic therapy for alcoholism protects Adial Pharmaceuticals (ADIL) from price wars, leaving risks solely within the realm of digital telemedicine. Quarterly earnings per share (EPS) dynamics measure the growth rate of net income, allowing investors to assess the fundamental value of the business and determine optimal entry points for this long-term asset through the quarterly history of EPS growth.

Who Adial Pharmaceuticals competes with

Indivior Corp (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Collegium Pharmaceutical Inc|CRON (thecronosgroup.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth canopygrowth.com|Quarterly EPS earnings growth HITI|ACB (Aurora Cannabis, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ACHV (Achieve Life Sciences, Inc)|Skye Bioscience (SKYE) - Earnings per share growth in annualized terms for the last twelve months|Anebulo Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months InterCure|NTRB: Quarterly EPS earnings growth|NSRX - Year-over-year net earnings per share change for the last twelve months|IGC (IGC Pharma Inc) - Quarterly EPS earnings growth|MIRA Pharmaceuticals - Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth FLGC|IM Cannabis - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth ARTL (Artelo)|Year-over-year earnings per one share growth for the last 12 months ENSC|Titan Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Greenlane Holdings|inmedpharma.com (INM) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months AKAN|Year-over-year earnings per share growth for the last twelve months Enveric Corp|Earnings per share growth in annualized terms for the last twelve months brightgreen.us BGXX|Year-over-year net earnings per share growth for the last 12 months HPCO (Hempacco Co Inc.)